Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)

NCT04368559 is registered in ClinicalTrials.gov with Mundipharma Research Limited as lead sponsor.

NCT NCT04368559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04368559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)
Lead sponsor
Mundipharma Research Limited
Phase
Phase 3
Overall status
Completed
Start date
May 11, 2020
Completion date
January 29, 2026
Enrollment
602 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

aspergillus, candidemia, fungal infection, fungemia, invasive candidiasis, invasive fungal disease, mold infection, mycoses, pneumocystis, prophylaxis of invasive fungal infections